Type 2 diabetes mellitus (T2DM) has characteristics of insulin resistance with impaired hyperglycemia. Incretin effect, oral glucose loading induced a greater insulin secretion response than that of an isoglycemic intravenous glucose infusion, had lead us to recognize the glucose lowering effect of gut hormones; glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). 1 These incretins are rapidly degraded by Dipeptidyl peptidase-4 (DPP-4), 2 and DPP-4 inhibitors improve glycemic control by slowing degradation of incretin hormones.
inhibitors with metformin, 5 insulin, 6, 7 and sulfonylurea 8, 9 also induced more favorable glycemic control than monotherapy. Previous meta-analysis 10 and prospective observational studies 11 have shown that the clinical predictors of therapeutic responses to DPP-4 inhibitors were 1) older age, 2) higher baseline glycated hemoglobin (HbA1c), 3 ) low beta-cell function, 4) short-duration of diabetes. Meanwhile, other studies 12, 13 
MATERIALS AND METHODS

Study subjects
From December 2012 to January 2014, adults over 20 year-old with T2DM who were not reached glycemic target (HbA1c > 6.5%), and were not previously prescribed DPP-4 inhibitors (sitagliptin/vildagliptin) were enrolled. Patients who already have been prescribed with all other kinds of anti-diabetic drugs were enrolled. They were excluded i) if they had short duration of follow-up (less than 6 months) or took DPP-4 inhibitors irregularly, ii) Patients who were diagnosed with Type 1 diabetes or secondary diabetes, or iii) there were lack of baseline anthropometric (weight, height) and biochemical parameters based on medical records. Other end-points included fasting plasma glu-cose (FPG), 1-hr postprandial plasma glucose (PP1). Responders were defined as those who showed decreased HbA1c more than 5% from baseline HbA1c after treatment. Non-responders were defined as those who showed no change or increase in HbA1c after treatment or those who stopped medication with DPP-4 inhibitors under clinical judgement for its effectiveness and compliance.
Study design
Statistical analysis
The baseline characteristics of patients were 
RESULTS
Baseline characteristics of study subjects
Efficacy of concomitant use with DPP-4 inhibitor
After an average 9.2 ± 1.8 months of follow-up period, fasting plasma glucose (on average 13 ㎎/ ㎗; P = 0.019), 1-hr postprandial glucose (29 ㎎/㎗; P = 0.002), and HbA1c (0.7%; P < 0.001) decreased significantly after adding DPP-4 inhibitors (Table   1 ). In subgroup analysis, add-on treatment with DPP-4 inhibitors showed that it reduced HbA1c by 0.87% with metformin monotherapy (n = 44, P < 0.001), by 0.63% with combination treatment of sulfonylurea and metformin (n = 62, P = 0.001), and by 0.72% with triple combination treatment (n = 27, P = 0.003) ( Fig. 1 ).
Difference in anthropometric and biochemical parameters between responders and non-responders
Responders (n = 84, 62.2%) who showed decreased HbA1c about more than 5% from baseline HbA1c had similar baseline anthropometric and biochemical characteristics compared with non-responders (n = 51, 37.8%), except on baseline fasting plasma glucose, HbA1c, and percentage of concomitant insulin usage ( Table 2) .
Multivariate logistic regression analysis showed that only higher HbA1c at baseline (odds ratio 2.07 with 95% confidence intervals 1.15 -3.72) was a significant predictive factor of therapeutic 
Safety and side effects of DPP-4 inhibitors
Hypoglycemia occurred in one patient who was 
DISCUSSION
This study has demonstrated that DPP-4 in- BMI, body mass index;SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; PP1, postprandial 1-hr glucose; HbA1c, glycated hemoglobin; TG, triglyceride; HDL, high-dense lipoprotein, HOMA2%B, homeostasis model assessment of pancreatic beta-cell function; HOMA2-IR, homeostasis model assessment of insulin resistance; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitor. for efficacy of DPP-4 inhibitor in drug-naïve patients with T2DM. Furthermore, meta-analytic studies also showed that high baseline HbA1c is most prominent predictive factors. 4, 16 Even though there are some discrepancies between studies which have different inclusion criteria and characteristics, many studies showed that efficacy of DPP-4 inhibitors was closely associated with high baseline HbA1c.
In better improvement in glycemic control, including postprandial glucose, 18 2) minimizing dose of basal insulin uptitration to achieve glycemic target, 19 and 3) reduced incidence of hypoglycemia. 20 In our study, average BMI of enrolled patients was 25.12 ㎏/㎡, and responders had a non-significantly lower BMI than non-responders (24.87 ㎏/㎡ versus 25.53 ㎏/㎡, P = 0.267). BMI is highly correlated with insulin sensitivity, 21 and Asians patients with T2DM have a different epidemiologic characteristics compared with Caucasians, who have higher BMI with insulin resistance, 22 whereas Asian patients with T2DM had a small amount of insulin beta-cell mass and deficiency in insulin secretion were prominent than Caucasians. 23 Previous study showed that HbA1c-lowering efficacy of DPP-4 inhibitors in T2DM was higher in Asians than in other ethnic groups, 24 and lower BMI was a predictor of a good response to DPP-4 inhibitors. 24, 25 During follow-up period in our study, there was one case (0.74%) of hypoglycemic event ( < 70 ㎎/ ㎗) who were co-prescribed with basal insulin.
Hypoglycemia is a major concern with anti-diabetic treatment, especially with sulfonylurea or insulin. 26 DPP-4 inhibitors were known to be well tolerated, and the incidence of hypoglycemia is lower than other oral anti-diabetic drugs. 27 In our study, weight gain after follow-up oc- 
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